Scarica l'app Stockscreener
28.62
4.02%
-1.20
Precedente Chiudi:
$29.82
Aprire:
$30.05
Volume 24 ore:
964.95K
Relative Volume:
1.21
Capitalizzazione di mercato:
$3.29B
Reddito:
$22.50M
Utile/perdita netta:
$-203.82M
Rapporto P/E:
-16.38
EPS:
-1.7469
Flusso di cassa netto:
$-148.03M
1 W Prestazione:
-4.15%
1M Prestazione:
-17.35%
6M Prestazione:
+18.31%
1 anno Prestazione:
+21.37%
Intervallo 1D:
$28.53
$30.74
Intervallo di 1 settimana:
$28.53
$31.71
Portata 52W:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
28.62 | 3.29B | 22.50M | -203.82M | -148.03M | -1.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-25 | Iniziato | Wells Fargo | Overweight |
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
(NAMSW) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Gains Report: Why is NewAmsterdam Pharma Company NV stock going down2026 Spike Watch & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Insider Sell: Louis Lange Sells 44,619 Shares of NewAmsterdam Ph - GuruFocus
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors - MarketBeat
Warrant exercise and trust sale at NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc. - MarketBeat
Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock - MarketBeat
Johannes Jacob Piete Kastelein Sells 101,409 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
(NAMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Trend Report: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullishMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma gives two new hires 10K options, 2,200 RSUs - Stock Titan
Stock Recap: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2025 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - Defense World
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan
Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily
Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat
NewAmsterdam Pharma CSO Sells Shares - TradingView
NewAmsterdam Pharma (NAMS) CSO executes 45,481-share stock sale - Stock Titan
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing - simplywall.st
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
NAMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Q1 Earnings Forecast for NAMS Issued By HC Wainwright - MarketBeat
Published on: 2026-02-22 03:05:00 - baoquankhu1.vn
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock beat analyst upgradesGap Up & Reliable Volume Spike Alerts - mfd.ru
What is HC Wainwright's Estimate for NAMS Q3 Earnings? - MarketBeat
6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
Cantor Fitzgerald Maintains Overweight on NAMS NewAmsterdam Pharma Feb 2026 - Meyka
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight - Investing.com Nigeria
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing - Investing.com Nigeria
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight By Investing.com - Investing.com Australia
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):